secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-133331
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 2.04, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated
--------------------------------------------------------------------------------

- Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
- Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.
- All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.
- Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.
- Audit of 2025 financials not completed; company will not file 10-K or any periodic reports.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/0001193125-26-133331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526133331/d87973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-133331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer